Project description
Simple outpatient treatment for acid reflux disease
Gastroesophageal reflux disease is a disorder of the digestive system caused by defects in the lower oesophageal sphincter, resulting in heartburn, regurgitation, and reflux of gastric acid and digestive enzymes. Very common in the EU, this condition is currently treated with symptomatic medications, which do not address the underlying cause. This EU-funded project aims to introduce minimally invasive outpatient treatment for this disease using injectable bulking agent to support endoscopic remodelling of the sphincter for a long-term cure. The procedure will involve injection of biocompatible polymethylmethacrylate microspheres to provide a scaffold for fibrovascular tissue ingrowth in the affected area. The first phase of the project will establish market strategy as well as the draft for the development plan.
Fields of science
Programme(s)
Call for proposal
H2020-SMEInst-2018-2020-1
See other projects for this call
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
E95EN London
United Kingdom
See on map